NEW YORK (December 9, 2024)—TB Alliance welcomes Srishti Gupta, MD, MPP, MPhil, and Akshay Vaishnaw, MB, BCh, PhD, FRCP, to its Board of Directors, bolstering the organization’s strategic and scientific leadership as it advances its mission to discover, develop, and deliver improved treatments for tuberculosis (TB).
“Srishti and Akshay bring invaluable perspectives in public health and biopharmaceutical innovation,” said David Norton, Chairman of the Board. “Their expertise will strengthen our efforts in developing and delivering life-saving TB treatments.”
Dr. Srishti Gupta, a physician with over 20 years of experience in global health and pharmaceuticals is currently an active member on several Boards, including Idorsia, Invivyd, and Partners in Health. During her 18 years at McKinsey, Dr. Gupta advised clients on topics of strategy, growth, and market access in the life sciences industry and spent more than 10 years leading the McKinsey Global Health Practice.
“I am honored to join the TB Alliance Board,” said Gupta. “I look forward to contributing to the organization’s strategic direction, ensuring that transformative solutions reach those who need them most.”
Dr. Akshay Vaishnaw, a leader in drug development and innovation, has spent the past 19 years at Alnylam Pharmaceuticals, most recently as President, where, as a founding member of the leadership team, he helped grow the organization to a pre-eminent biotechnology company in RNA interference therapeutics. He is currently a partner at Atlas Ventures and serves as a member of several Boards, including Hemab Therapeutics and Scholar Rock.
“TB Alliance’s dedication to pioneering innovation in TB treatment is unprecedented,” said Vaishnaw. “I look forward to being a Board member as the organization continues its groundbreaking advancements for treatment of TB.”
With these appointments, TB Alliance expands the breadth of its leadership and further positions the organization for continued success.